PROX2

Across TCGA pan-cancer cohorts, PROX2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of PROX2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PROX2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PROX2 is over-expressed in tumor, although a few such as BRCA and THCA show the opposite, repressed pattern.

HNSC, BRCA, and CHOL are the cancer types where PROX2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PROX2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.085	<.001	9	view →
BRCA	All	III,IV	−0.221	<.001	6	view →
CHOL	All	All	+0.230	.001	5	view →
KICH	All	II,III,IV	+0.172	.002	4	view →
LIHC	All	All	+0.030	<.001	4	view →
THCA	All	All	−0.162	<.001	3	view →
KIRC	Male	All	+0.052	.019	2	view →
STAD	Male	II,III,IV	+0.119	.031	1	view →
KIRP	Male	All	−0.067	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

PROX2–HNSC

Open the HNSC breakdown →